Researchers Offer Antibodies Targeting a Viral Clue in Liver Cancer
Published Date: 8/12/2026
Notice
Summary
The National Cancer Institute has created special human antibodies that target a unique viral peptide linked to liver cancer. These antibodies could help treat liver cancer more effectively, especially for patients who don’t respond well to current therapies. Researchers and companies interested in developing these treatments can now license this invention and start working on it.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Potential New Treatment for Liver Cancer
NCI-developed human anti-CE1 antibodies (B9 and B10) specifically bind liver cancer cells and inhibited hepatocellular carcinoma (HCC) tumor growth via natural killer cell-mediated antibody-dependent cellular cytotoxicity in vitro and in vivo. The antibodies are described as having potential to be used as liver cancer therapeutics, including development of treatments that overcome PD-1/PD-L1 checkpoint blockade resistance; the technology is at pre-clinical in vivo validation.
NCI Offering License for Anti-CE1 Antibodies
The National Cancer Institute (NCI) is offering a license/co-development opportunity for a collection of human anti-CE1 antibodies (NIH Reference Number: E-021-2025) intended for liver cancer treatment. The technology is at the pre-clinical stage (in vivo validation) and a provisional patent was filed on August 8, 2025; interested parties should contact Michael Pollack, Ph.D., at 240-276-5519 for licensing inquiries.
Preclinical Model and Screening Tool Available
The notice identifies a companion preclinical model using the MC38 colon cancer system (including B2m knockout versus wild-type comparisons) that uniquely models checkpoint-resistance mechanisms and is described as regulatorily de-risked (Related Technology NIH Ref: E-023-2024). NCI lists this model as available for development, preclinical screening, and licensing collaboration.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-21816, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review at the National Institutes of Health is holding several closed virtual meetings in November 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets while deciding which research projects get funding. Scientists applying for grants in areas like molecular protein interactions, infectious disease, and cancer immunotherapy should note these important review dates.
2026-21689, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in November 2026 to review and evaluate grant applications. These meetings affect researchers and small businesses seeking funding, ensuring their confidential info stays private. No new costs or deadlines are introduced, but these reviews are key steps in funding important scientific projects.
2026-21688, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in November 2026 to review and evaluate grant applications. These meetings affect researchers applying for funding in areas like cardiovascular health, environmental diseases, and nanotechnology. No public access is allowed to protect private info and trade secrets, but these reviews help decide who gets research money.
2026-21527, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in November 2026 to review and evaluate grant applications. These meetings affect researchers and small businesses seeking funding for scientific projects, especially in biophysics, immunology, neurodegenerative disorders, and anti-infective therapies. No public access is allowed to protect private and sensitive information, but these reviews help decide who gets research money.
2026-21526, Center for Scientific Review; Notice of Closed Meetings
The NIH’s Center for Scientific Review is holding several closed virtual meetings in November 2026 to review and decide on grant applications. These meetings protect private info and trade secrets while helping decide who gets funding for important health research. If you’re involved in health or small business research grants, these reviews could impact your funding timeline and opportunities.
2026-21525, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in November 2026 to review important grant applications related to health research. These meetings protect private info and trade secrets while deciding which projects get funding. Scientists and small businesses applying for grants will be affected, with no changes to timing or money announced.
Previous / Next Documents
Previous: 2026-16441, Government Owned Invention Available for License: DNA Methylation-Based Cancer Diagnostics for Accurate Tumor Classification
The government has created a cool new tool that uses DNA patterns to help doctors classify cancer tumors more accurately, especially in the brain, kidney, and blood. This tech cuts down on guesswork and makes diagnoses clearer, helping patients get the right treatment faster. It’s ready for licensing now, so companies can bring this game-changing cancer test to clinics and labs soon.
Next: 2026-16443, Government Owned Invention Available for License: Monoclonal Antibody (RO4) That Reacts With the Juxta-Membrane Region of Mesothelin
The National Cancer Institute (NCI) seeks research co- development partners and/or licensees for a novel monoclonal antibody (mAb), RO4, that can be used to treat mesothelin (MSLN) expressing cancers.